Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Parallel-group, Multi-centre, Phase I/III Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Once-daily Oral Administration of D961H 10 mg and D961H 20 mg in Japanese Paediatric Patients 1 to 14 Years Old With Gastrointestinal Acid Related Diseases

NCT02153398 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02153398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02153398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Parallel-group, Multi-centre, Phase I/III Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Once-daily Oral Administration of D961H 10 mg and D961H 20 mg in Japanese Paediatric Patients 1 to 14 Years Old With Gastrointestinal Acid Related Diseases
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2014
Completion date
April 30, 2016
Enrollment
55 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

anastomotic ulcer (au), duodenal ulcer (du), gastric ulcer (gu), non-erosive reflux esophagitis disease (nerd), reflux esophagitis (re), zollinger-ellison syndrome